News
WCG Expands Clinical Trial Technology and Services with Acquisition of VeraSci
WCG today announced the acquisition of VeraSci, a global provider of specialty scientific expertise and eClinical software to support the design and execution of clinical trials focused on central nervous system (CNS) disorders. The addition of VeraSci, based in...
How Can Clinical Trial Data Be Returned to Study Participants in a Compliant and Ethical Manner?: New IMI-2 Funded Project Seeks Answers
The Framework for Clinical Trial Participants’ Data Reutilization for a Fully Transparent and Ethical Ecosystem (FACILITATE) is a new Innovative Medicines Initiative (IMI) funded project to find an ethical and GDPR compliant framework for returning clinical trial data...
New Approaches for the Value Assessment of Advanced Medical Products
The journal Clinical Drug Investigation recently published the article “New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing” which was co-authored by Dr. Luca Pani, VP Regulatory Strategy and...
VeraSci Partners with Boehringer Ingelheim on Innovative Phase III Program for Breakthrough Therapy in Cognitive Impairment Associated with Schizophrenia
Today, Boehringer Ingelheim announced that they are partnering with VeraSci on an innovative phase III program in cognitive impairment associated with schizophrenia (CIAS) for the investigational treatment BI 425809. The FDA has granted Breakthrough Therapy...
Recent Innovations and their Regulatory Implications for Multiple Sclerosis Trials Addressed in a Special Issue of the Journal of Clinical Neurophysiology by VeraSci Experts
This week, the Journal of Clinical Neurophysiology published a special issue about recent innovations and their regulatory implications for clinical trials in multiple sclerosis. Dr. Mark Skeen, Senior Medical Scientist at VeraSci and Professor of Neurology at Duke...
What Other Countries Can Learn from Italy’s Creative Market Access Agreements
The 20Sense Report, a quarterly publication for Canada’s specialty pharmaceutical industry, featured VeraSci’s Dr. Luca Pani in their April 2021 issue discussing creative approaches to market access. The article compares the agreements that have been used in Italy to...
VeraSci Partners with Aural Analytics to Incorporate Speech Analytics into Pathway eCOA Platform
VeraSci—a global clinical research company offering eClinical software, translation services, and expertise in endpoints and assessments—is pleased to announce a new partnership with Aural Analytics, Inc., a global leader in speech analytics for clinical research....
VeraSci Partners with ActiGraph to Expand the Use of Wearables in Clinical Trials
Durham, NC—January 19, 2021—VeraSci—a global clinical research company offering eClinical software, translation services, and expertise in endpoints and assessments—is pleased to announce a new partnership with ActiGraph, a leading provider of medical-grade wearable...
VeraSci Sees Continued Growth Despite COVID-19 Challenges Faced by Clinical Trials Industry
Durham, NC—December 18, 2020—VeraSci—a global clinical research company offering eClinical software, translation services, and expertise in endpoints and assessments—is concluding a successful year marked by extensive hiring and expanded service offerings. This growth...
Study Supporting Effectiveness of the Placebo-Control Reminder Script (PCRS) Published in Neuropsychopharmacology
Neuropsychopharmacology recently published “Placebo Response Mitigation with a Participant-Focused Psychoeducational Procedure: A Randomized, Single-Blind, All Placebo Study in Major Depressive and Psychotic Disorders”. Dr. Bill Horan, Vice President Clinical Science...